COMMUNIQUÉS West-GlobeNewswire

Cemdisiran, Dosed Subcutaneously Every 12 Weeks, Demonstrates Rapid, Deep and Sustained Disease Control in Generalized Myasthenia Gravis (gMG) Phase 3 Trial
21/04/2026
As published in The Lancet and presented at AAN, NIMBLE trial met its primary and key secondary endpoints at week 24, demonstrating potential best-in-class efficacy and convenience in gMG U.S. regulatory application [...]
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer
21/04/2026
Results from Part 1 of the Phase 1b MUIR trial to be presented at annual meeting in June SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator [...]
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
21/04/2026
Houston, Texas and Tuebingen, Germany, April 21, 2026 – Immatics N.V. (NASDAQ: IMTX, “Immatics” or the “Company”), the global leader in precision targeting of PRAME with multiple clinical-stage programs spanning cell [...]
NextCure and Simcere’s SIM0505 (CDH6 ADC) Phase 1 Data to be Presented at ASCO 2026
21/04/2026
Poster to be presented at the American Society for Clinical Oncology on Monday, June 1, 2026 BELTSVILLE, Md., April 21, 2026 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company [...]
Aprea Therapeutics to Provide Clinical Update on ACESOT-1051 Phase 1 Trial Evaluating WEE1 Inhibitor, APR-1051, at ASCO 2026 Annual Meeting
21/04/2026
DOYLESTOWN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage precision medicine oncology company focused on the discovery and development of [...]
Dewpoint Therapeutics Reports Preclinical Data on Oral MYC Condensate Modulator at AACR 2026
21/04/2026
Oral MYC condensate modulator drives tumor regression and stasis in preclinical models Disruption of MYC condensates enables targeted inhibition of MYC-driven gene expression Selective killing in cells with high levels [...]
Cardiff Oncology to Present Updated Phase 2 Data of Onvansertib in First-Line RAS-Mutated mCRC in a Rapid Oral Session at ASCO 2026
21/04/2026
SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced it will present [...]
Disc Medicine Announces Oral Presentation of Data from RALLY-MF Phase 2 Trial of DISC-0974 in Patients with Myelofibrosis and Anemia at the American Society of Clinical Oncology (ASCO) Annual Meeting
21/04/2026
WATERTOWN, Mass., April 21, 2026 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for [...]
ACTG Launches Critical Study Evaluating Hormone Therapy for Women Living with HIV in the Menopause Transition
21/04/2026
CHAPEL HILL, N.C., April 21, 2026 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of the HoT study (Menopausal Hormone Therapy for [...]
Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026
21/04/2026
To Highlight Efficacy Results from Relapsed or Refractory Waldenström Macroglobulinemia Patients Treated with Iopofosine I 131 Immediately Following BTK Inhibitor Therapy FLORHAM PARK, N.J., April 21, 2026 (GLOBE [...]
ImPact Biotech Announces Upcoming Data Presentations for Padeliporfin VTP at AUA and ASCO 2026
21/04/2026
– Company to present updated data from the Phase 3 ENLIGHTED trial of Pa deliporfin VTP in LG UTUC with topline data expected in 2026 – – Additional preliminary data from the Phase 1 trial in LA-PDAC to be presented at [...]
Leads Biolabs' PD-L1/4-1BB Bispecific Antibody Opamtistomig (LBL-024) Enters Phase Ⅱ Trial with First Patient Dosing in Gastric Cancer, Pioneering Enhanced Immunotherapy Combination Strategies
21/04/2026
NANJING, China, April 21, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the first patient has been successfully dosed in a phase Ⅱ [...]
Lachine Hospital Foundation Gala raises $322,115 to transform health care in the West Island
21/04/2026
DORVAL, Quebec, April 21, 2026 (GLOBE NEWSWIRE) -- The Lachine Hospital Foundation’s signature gala raised $322,115 in support of the Dream Big: Lachine Hospital campaign—a powerful collaboration with the MUHC [...]
Le Gala de la Fondation de l’Hôpital de Lachine recueille 322 115 $ pour transformer les soins de santé dans l’Ouest-de-l’Île
21/04/2026
DORVAL, Québec, 21 avr. 2026 (GLOBE NEWSWIRE) -- Le Gala de la Fondation de l’Hôpital de Lachine a permis de recueillir 322 115 $. Cette somme servira à soutenir la campagne Osez rêver : Hôpital de Lachine , un [...]
Eclipse Energy and Wood to Scale Hydrogen Production from End-of-Life Oil Fields
21/04/2026
Strategic collaboration positions Wood as a preferred engineering partner as Eclipse moves its reservoir-to-hydrogen technology toward global project development HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- As demand [...]
Moleculin Announces Abstract Accepted for Poster Presentation at the 2026 ASCO Annual Meeting
21/04/2026
HOUSTON, April 21, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced that an abstract highlighting data on its lead drug candidate, annamycin, has been [...]
Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call
21/04/2026
MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life [...]
Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™
21/04/2026
Payer access for Emrosi™ expanded from approximately 100 million commercial lives to over 150 million commercial lives as of April 1, 2026 SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical [...]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Leveraging Expertise amid Evaluation Evolution
21/04/2026
NEW YORK, April 21, 2026 (GLOBE NEWSWIRE) -- via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic [...]

Pages